An alcohol interaction study of Hydromorphone extended-release for evaluation of abuse-deterrent capabilities
Phase of Trial: Phase I
Latest Information Update: 03 Jan 2017
At a glance
- Drugs Hydromorphone (Primary)
- Indications Pain
- Focus Pharmacodynamics; Pharmacokinetics
- 03 Jan 2017 This trial was planned by Flamel Technologies. The company has completed cross-border merger and became Avadel Pharmaceuticals plc, according to a Flamel Technologies media release.
- 13 Sep 2016 New trial record
- 08 Aug 2016 According to a Flamel Technologies media release, following guidance from FDA the company will be conducting an alcohol interaction study in the second half of 2016.